Cysteamine Precursor Formulations for Controlled Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cysteamine formulations face challenges such as unpleasant sensory properties, gastrointestinal side effects, unstable nature, and inadequate dosing regimens, leading to poor compliance and limited therapeutic efficacy due to high peak concentrations and short duration of action.
Innovation Solution
Development of pharmaceutical compositions containing cysteamine precursors that can be degraded to cysteamine in the gastrointestinal tract, along with enhancers to optimize chemical and enzymatic reactions, absorption, and half-life, allowing for tailored dosing regimens to maintain therapeutic levels while minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If immediate release formulations of cysteamine are used, then rapid therapeutic effect is achieved, but peak concentrations cause severe gastrointestinal side effects and halitosis
Solution Approach 1:
The invention segments the single dose into multiple controlled-release units (capsules or tablets) that release cysteamine at different rates and times. Each unit contains cysteamine combined with a different release-modifying agent, creating a stepped release pattern that maintains therapeutic levels while avoiding peak concentrations that cause side effects.
Solution Approach 2:
The invention uses dynamic release profiles where the rate of cysteamine release changes over time. The combination of different release-modifying agents creates a dynamic system that adapts the release rate to maintain therapeutic efficacy while minimizing toxic peak levels, rather than using a static immediate-release formulation.
2Object-affected harmful factors
If enteric coated formulations are used, then gastrointestinal side effects are reduced, but absorption efficiency and bioavailability are compromised
Solution Approach 1:
Instead of using a single enteric coating that compromises absorption, the invention segments the formulation into multiple units with different coating strategies. Some units use enteric coatings to protect against gastric irritation, while others use permeable matrices that optimize absorption, creating a balanced approach that maintains both tolerability and bioavailability.
Solution Approach 2:
The invention uses composite formulation strategies where different release-modifying agents with distinct properties are combined. This includes mixing enteric-coated particles with permeable matrix materials, creating a composite system that leverages the advantages of both approaches - protection from gastric irritation and optimized absorption.
3Duration of action of moving object
If sustained release formulations are used, then therapeutic levels are maintained longer, but inter-patient variability in release profiles increases
Solution Approach 1:
The invention segments the sustained-release problem into multiple controllable units. Each unit has a defined release profile, and the combination of units creates an additive effect that extends therapeutic duration. This segmentation allows for more predictable and consistent overall release patterns compared to single-unit sustained-release formulations, reducing inter-patient variability.
4Quantity of substance
If high doses are administered, then therapeutic efficacy is improved, but peak concentrations exceed safe thresholds causing toxicity
Solution Approach 1:
The invention divides the total therapeutic dose into multiple smaller units administered simultaneously or sequentially. Each unit contains a sub-therapeutic amount of cysteamine combined with release-modifying agents. The cumulative effect of multiple units achieves the required therapeutic dose while each unit releases cysteamine at safe, non-toxic rates, avoiding peak concentration toxicity.
Solution Approach 2:
The invention creates a dynamic dosing strategy where the total dose is distributed across multiple release profiles. The combination of different release rates creates a dynamic release pattern that maintains therapeutic levels without exceeding safe peak concentrations, effectively managing the total quantity while controlling the rate of delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach enables sustained therapeutic levels of cysteamine with reduced peak concentrations, improving efficacy and compliance by exploiting the gastrointestinal tract's cysteamine-producing capacity, thereby addressing inter-patient variability and stability issues.
Implementation Method 1
pharmaceutical compositions containing cysteamine precursors that can be degraded to cysteamine in the gastrointestinal tract
Implementation Method 2
enhancers to optimize chemical and enzymatic reactions, absorption, and half-life
Implementation Method 3
increase the absorption of cysteamine across the gastrointestinal epithelium
Data Source
AI summary
The invention features compositions, methods, and kits containing (i) one or more cysteamine precursor compounds convertible to cysteamine in vivo, and (ii) optionally agents to enhance that conversion, formulated to produce a spectrum of pharmacokinetic profiles of cysteamine that can be tailored to individual patients and diseases. The invention also features varying modes of administration of the therapeutic substances in the treatment of cystinosis and other cysteamine sensitive disorders. In particular, formulations combining active ingredient(s) with pharmaceutical excipients that permit sustained cysteamine plasma concentrations are featured.